IMPALA (Inter coMPany quALity Analytics)

What IMPALA (Inter coMPany quALity Analytics) does

IMPALA (Inter coMPany quALity Analytics) is a global, non-profit consortium operating under IEEE-ISTO that brings together more than 19 leading biopharmaceutical companies and health authorities to drive industry-wide adoption of digital and advanced analytics methodologies for clinical quality assurance. Founded informally in 2019 and formally launched as an IEEE-ISTO member program in October 2022, IMPALA focuses on the Good Clinical Practice (GCP) and Good Pharmacovigilance Practice (GVP) domains, with the stated mission of replacing retrospective, manually intensive audits with proactive, data-driven continuous monitoring that reduces quality-issue detection latency and accelerates patient access to therapies. The consortium is governed by a member-driven structure with health authority partners including FDA, EMA, MHRA, PMDA, and NMPA participating at no cost.

Name

IMPALA (Inter coMPany quALity Analytics)

Legal name

IMPALA Consortium

Website

https://impala-consortium.org

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Biopharmaceutical Clinical Quality Analytics

NAICS

Other Scientific and Technical Consulting Services (541690)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Data Management, Biostatistics & Statistical Programming FSP (HLAGAOAB)

Keywords

• Clinical trial analytics
• Pharmacovigilance quality
• Adverse event detection
• Biopharmaceutical quality assurance
• Risk-based quality management

Headquarters

HQ city

Piscataway

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Membership Dues: IMPALA generates revenue through annual membership fees from biopharmaceutical companies. Governing Board Level members pay US $15,000 annually, Bio Pharma Sponsor Level members pay US $7,500 annually, and Health Authority Partners receive free membership.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

IMPALA is a cross-industry consortium that develops and shares open-source tools, methodologies, and best practices for applying advanced analytics to biopharmaceutical quality assurance in Good Clinical Practice (GCP) and Good Pharmacovigilance Practice (GVP) areas. Its core offerings include open-source R packages (CTAS for clinical trial anomaly detection and simaerep for adverse event under/over-reporting detection), methodology frameworks (Quality Briefs, RAPID Audit, CAR, Audit Site Selection), and the Data Analytics for Quality Assurance Framework. The consortium operates through annual membership tiers and engages health authorities for regulatory alignment.

Product overview

IMPALA is a collaborative consortium, not a single software product company. Its portfolio consists of open-source R packages, methodology frameworks, and guidance documents shared publicly to advance analytics-driven quality in biopharma. The core software tools are {simaerep} (adverse event under/over-reporting detection) and CTAS (clinical trial anomaly detection in time series). These are complemented by methodology frameworks including Quality Briefs, RAPID Audit, Critical to Quality Assessment Report (CAR), and Audit Site Selection methodologies, plus the Data Analytics for Quality Assurance in Pharmaceutical Development Framework. IMPALA also produces educational resources including a podcast series. AI capabilities span NLP for regulatory intelligence, GenAI for audit report drafting, and predictive/advanced analytics across all tools. All software is distributed as open-source R packages via GitHub, not as licensed SaaS products.

Differentiator

Problem solved

Functional benefit

Brands

• CTAS (Clinical Trial Anomaly Spotter): Open-source R package for identifying outliers and anomalies efficiently and accurately in clinical trial time series.
• simaerep
• Quality Briefs
• CAR (Critical to Quality Assessment Report)
• RAPID Audit
• AI Powered Regulatory Intelligence

Products and services

• CTAS (Clinical Trial Anomaly Spotter) Open-source R package for Central Statistical Monitoring that identifies outliers and anomalies efficiently and accurately in clinical trial time series. Flags sites with one or more study parameters whose profiles differ from those of other sites, and identifies anomalies for individual subjects. Distributed via GitHub.
• Data Analytics for Quality Assurance in Pharmaceutical Development Framework Guidance document and framework offering insights and guidance on transforming Quality Assurance in GCP and GVP through advanced analytics. Provides organizations direction in developing, implementing, and enhancing their analytics and technology strategy.
• RAPID Audit (Real-time Audit Package Informed by Data) A data-driven audit methodology that follows a pre-defined approach to assess processes, identify systemic issues, and provide insights into GCP and GVP compliance efficiently at scale.
• Critical to Quality Assessment Report (CAR) A risk management and quality assurance methodology that supplements GCP inspections by providing transparency through CtQ-based risk assessment, a Quality Assurance Strategy, and Evidence Generation leading to quality conclusions.
• Quality Briefs A regulatory concept and output of Risk-Based Quality Management (RBQM) that provides transparency on quality issues, mitigations, and their impact throughout the drug development process, supporting innovation and expedited patient access to new therapies.
• AI Powered Regulatory Intelligence AI-powered methodology that streamlines the monitoring and implementation of evolving regulatory guidelines by analyzing new changes at scale and highlighting their impact on the QMS landscape.
• Audit Site Selection Data-driven approach to selecting clinical investigator sites for audit based on risk factors, improving audit site selection efficiency and accuracy through advanced analytics.

Quantifiable outcome

• simaerep identified 50% of all detectable sites as early as 25% into the designated study duration
• +1 more outcomes

Named customers14 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered major and core.

• RQA (Research Quality Association)majorStrategic or Co-development Partner · 10 May 2023RQA features IMPALA sessions and collaborations, including the Certificate in Data Basics eLearning partnership with Roche. RQA Quality Conversation sessions highlight IMPALA's work and open-source tools.
• FDA (U.S. Food and Drug Administration)coreStrategic or Co-development Partner · 1 July 2019FDA participates as a Health Authority Partner in IMPALA, providing feedback on quality analytics methodologies and engaging in collaborative discussions on regulatory expectations. FDA representatives have participated in IMPALA sessions at DIA conferences.
• EMA (European Medicines Agency)coreStrategic or Co-development Partner · 1 July 2019EMA participates as a Health Authority Partner in IMPALA, engaging in discussions on AI in drug development and regulatory alignment. EMA representatives have participated in IMPALA sessions on AI in the medicinal product lifecycle.
• MHRA (Medicines and Healthcare products Regulatory Agency)coreStrategic or Co-development Partner · 1 July 2019MHRA participates as a Health Authority Partner, providing feedback on Critical to Quality Assessment methodologies and engaging in panel discussions on quality analytics at industry conferences.
• DIA (Drug Information Association)majorStrategic or Co-development Partner · 1 July 2019DIA provides conference platforms where IMPALA presents sessions and showcases work products. IMPALA has participated in DIA Global (Boston 2023, San Diego 2024, Washington DC 2025) and DIA China (SuZhou 2024) annual meetings.
• IEEE-ISTOcoreStrategic or Co-development PartnerIMPALA Consortium operates as a member program of IEEE-ISTO (Institute of Electrical and Electronics Engineers - International Society of Technology Optimization), which provides the governance framework and operational infrastructure for the consortium. IEEE-ISTO announced the formation of IMPALA Consortium in October 2022.
• PMDA (Pharmaceuticals and Medical Devices Agency)coreStrategic or Co-development PartnerPMDA is listed as an eligible Health Authority Partner organization for IMPALA membership, enabling regulatory engagement with Japanese pharmaceutical regulatory authorities.
• NMPA (National Medical Products Administration)coreStrategic or Co-development PartnerNMPA is listed as an eligible Health Authority Partner organization for IMPALA membership, enabling regulatory engagement with Chinese pharmaceutical regulatory authorities.

Scale indicators1 record

Recent moves7 records

Expansion highlights6 records

Direct peers

• Clinical Data Interchange Standards Consortium (CDISC): Non-profit organization developing data standards for clinical research. Comparable mission of advancing clinical trial data quality and interoperability through cross-industry collaboration and published standards.
• Critical Path Institute (C-Path): Independent, non-profit organization working with FDA and industry to accelerate drug development through regulatory science and shared data initiatives. Comparable public-private consortium model engaging regulators and sponsors.
• BioPhorum: Life sciences industry collaboration organization with multiple Phorums covering development, manufacturing, and supply chain. Comparable consortium-style model of member biopharma companies collaborating on shared industry improvements.
• TransCelerate BioPharma: Industry-funded, non-profit consortium of biopharmaceutical companies focused on collaborating to improve the efficiency and quality of clinical trials. Highly comparable consortium model with shared work products and member dues.
• Clinical Trials Transformation Initiative (CTTI): Public-private partnership co-founded by Duke University and FDA to improve the quality and efficiency of clinical trials. Comparable cross-stakeholder consortium working on clinical trial quality methodologies.
• PhUSE (Pharmaceutical Users Software Exchange): Non-profit organization providing a neutral platform for pharmaceutical industry users to share computing practices, data, and analytics standards. Comparable volunteer-driven industry collaboration on biopharma data/analytics.

Emerging players

• OpenClinica: Open-source clinical trial software for electronic data capture and clinical data management. Comparable open-source approach to clinical trial tooling, though focuses on EDC rather than central statistical monitoring.

Others

• International Council for Harmonisation (ICH): Global body that brings together regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of drug registration. Comparable regulator-engagement model that IMPALA's work products align with.

Broad incumbents

• Drug Information Association (DIA): Global life sciences membership association that hosts conferences, training, and publications. Directly comparable industry body in which IMPALA participates and presents; DIA is a broader incumbent in life sciences professional exchange.
• Medidata Solutions: Major technology provider for clinical trials (now part of Dassault Systèmes) offering RBQM, central statistical monitoring, and trial analytics. Comparable in product category (clinical trial quality analytics) but operates as a commercial vendor rather than a consortium.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• GitHubgithub.com/IMPALA-Consortium/ctas
• LinkedInlinkedin.com/company/inter-company-quality-analytics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IMPALA (Inter coMPany quALity Analytics)